Literature DB >> 25543285

Identification of the major degradation pathways of ticagrelor.

Hassane Sadou Yayé1, Philippe-Henri Secrétan2, Théo Henriet2, Mélisande Bernard3, Fatma Amrani4, Wiem Akrout4, Patrick Tilleul5, Najet Yagoubi2, Bernard Do3.   

Abstract

Ticagrelor is a direct-acting and reversible P2Y12-adenosine diphosphate (ADP) receptor blocker used as antiplatelet drug. Forced degradation under various stress conditions was carried out. The degradation products have been detected and identified by high-pressure liquid chromatography multistage mass spectrometry (LC-MS(n)) along with high-resolution mass spectrometry. C18 XTerra MS column combined with a linear gradient mobile phase composed of a mixture of 10 mM acetate ammonium/acetonitrile was shown suitable for drug and impurity determinations and validated as a stability indicating method. Structural elucidation of the degradation products relied on MS(n) studies and accurate mass measurements giving access to elemental compositions. Up to nine degradation products resulting from oxidation/auto-oxidation, S-dealkylation and N-dealkylation have been identified, covering a range of possible degradation pathways for derivatives with such functional groups. Kinetics was also studied in order to assess the molecule's shelf-life and to identify the most important degradation factors.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Degradation kinetic; Degradation pathways; Electrospray orbitrap mass spectrometry; LC stability-indicating assay method; Ticagrelor

Mesh:

Substances:

Year:  2014        PMID: 25543285     DOI: 10.1016/j.jpba.2014.11.046

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  Therapeutic Treatment Plan Optimization during the COVID-19 Pandemic: A Comprehensive Physicochemical Compatibility Study of Intensive Care Units Selected Drugs.

Authors:  Maria Gloria Tarantini; Stéphanie Ramos; Philippe-Henri Secrétan; Laura Guichard; Lamia Hassani; Agnès Bellanger; Julien Mayaux; Patrick Tilleul; Fadwa El Kouari; Hassane Sadou Yayé
Journal:  Pharmaceutics       Date:  2022-02-28       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.